http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2007061130-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate | 2006-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2007061130-A1 |
| titleOfInvention | Antitumor agent for multiple myeloma |
| abstract | An object of the present invention is to provide a living body including at least one selected from the group consisting of cells overexpressing FGFR3, cells translocated with t (4; 14), and cells expressing mutant FGFR3. Thus, it is an object of the present invention to provide a pharmaceutical composition and a treatment method that exert more effective effects. The compound represented by the general formula (I), or a pharmacologically acceptable salt thereof, or a solvate thereof includes a cell overexpressing FGFR3, a t (4; 14) translocated cell, and An effect can be exhibited more effectively for a living body including at least one selected from the group consisting of cells expressing mutant FGFR3. |
| priorityDate | 2005-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 236.